Novel therapeutic targets in inflammatory bowel disease

SMAD7 antisense oligonucleotides and sphingosine-1-phosphate receptor modulators are new oral agents that are being investigated as potential treatments for inflammatory bowel disease (Crohn’s disease and ulcerative colitis). This article reports on some of the clinical trial outcomes so far.

Read the full article.

Add yours ↓
Web design and marketing agency Leamington Spa